Testosterone inhibits the activity of peroxisome proliferator-activated receptor γ in a transcriptional transaction assay

Pharmazie

Volumn 64, Issue 10, 2009, Pages 692-693

  Du, J ^a   Zhang, L ^a   Wang, Zhao ^a  

^a Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; FLUTAMIDE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TESTOSTERONE; ANTIANDROGEN; ANTIDIABETIC AGENT; HYPERGLYCEMIC AGENT;

ADIPOGENESIS; ARTICLE; ASSAY; BODY COMPOSITION; BODY FAT; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIPID METABOLISM; MALE; RECEPTOR UPREGULATION; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; OBESITY; UPREGULATION;

ADIPOSITY; ANDROGEN ANTAGONISTS; CELL LINE; FLUTAMIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTAGONISTS; MALE; PPAR GAMMA; TESTOSTERONE; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 74949085842     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9606     Document Type: Article

References (13)

1. Al-Rasheed NM, Chana RS, Baines RJ, Willars GB, Brunskill NJ (2004) Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 279: 49747-49754.
2. Bhasin S, Woodhouse L, Storer TW (2001a) Proof of the effect of testosterone on skeletal muscle. J Endocrinol 170: 27-38.
3. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW (2001b) Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281: E1172-1181.
4. De Pergola G (2000) The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 24 Suppl 2: S59-63.
5. Gregoire FM, Smas CM, Sul HS (1998) Understanding adipocyte differentiation. Physiol Rev 78: 783-809.
6. Heinlein CA, Chang C (2002) The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181-2187.
7. Katznelson L, Rosenthal DI, Rosol MS, Anderson EJ, Hayden DL, Schoenfeld DA, Klibanski A (1998) Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol 170: 423-427.
8. MacDougald OA, Mandrup S (2002) Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 13: 5-11.
9. Rosen ED, Spiegelman BM (2000) Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16: 145-171.
10. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S (2003) Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144: 5081-5088.
11. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85: 2670-2677.
12. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85: 2839-2853.
13. Wilson JD (1988) Androgen abuse by athletes. Endocr Rev 9: 181-199.